NCT06258330View on ClinicalTrials.gov

Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

July 7, 2024

Study Completion Date

October 1, 2024

Conditions
Solid Tumor
Interventions
DRUG

AM003

Bispecific Personalized Aptamer for intratumoral administration

Trial Locations (5)

49100

Rabin Medical Center, Petah Tikva

Unknown

Rambam Health Care Campus, Haifa

Hadassah Medical Center, Jerusalem

Sheba Medical Center, Ramat Gan

Tel Aviv Sourasky Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Aummune Ltd.
All Listed Sponsors
lead

Aummune Ltd.

INDUSTRY

NCT06258330 - Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter